Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,400 shares, a growth of 110.0% from the October 15th total of 4,000 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 29,500 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A number of large investors have recently bought and sold shares of BRNS. Catalina Capital Group LLC bought a new position in shares of Barinthus Biotherapeutics in the second quarter worth about $25,000. Ipswich Investment Management Co. Inc. bought a new position in shares of Barinthus Biotherapeutics in the second quarter worth about $32,000. BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics in the first quarter worth about $1,292,000. DC Funds LP bought a new position in shares of Barinthus Biotherapeutics in the first quarter worth about $1,528,000. Finally, Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics in the second quarter worth about $2,119,000. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock remained flat at $1.40 during trading hours on Wednesday. 59,918 shares of the company's stock were exchanged, compared to its average volume of 23,842. The company has a market cap of $56.32 million, a P/E ratio of -0.95 and a beta of -0.59. Barinthus Biotherapeutics has a 12-month low of $1.11 and a 12-month high of $4.16. The stock has a fifty day moving average price of $1.29 and a 200 day moving average price of $1.55.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter last year, the firm earned ($0.37) EPS. On average, sell-side analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on BRNS shares. Alliance Global Partners decreased their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday, November 8th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.